Literature DB >> 9707189

Migrainous visual accompaniments are not rare in late life: the Framingham Study.

C A Wijman1, P A Wolf, C S Kase, M Kelly-Hayes, A S Beiser.   

Abstract

BACKGROUND AND
PURPOSE: Questionnaires to elicit symptoms of transient ischemic attacks (TIAs) may detect late-life transient visual symptoms similar to the visual aura of migraine, often without headache. We determined the frequency, characteristics, and stroke outcome of these symptoms in the Framingham Study.
METHODS: During 1971-1989, at biennial examinations, 2110 subjects of the Framingham cohort were systematically queried about the occurrence of sudden visual symptoms.
RESULTS: Visual migrainous symptoms were reported by 1.23% (26/2110) of subjects (1.33% of women and 1.08% of men). In 65% of subjects the episodes were stereotyped, and they began after age 50 years in 77%. Mean +/- SD age at onset of the episodes was 56.2+/-18.7 years. In 58% of subjects the episodes were never accompanied by headaches, and 42% had no headache history. The number of episodes ranged from 1 to 500 and was 10 or more in 69% of subjects. The episodes lasted 15 to 60 minutes in 50% of subjects. Sixty-five percent of the subjects were examined by a study neurologist, and only 19% of them met the criteria of the International Headache Society. Twelve percent of subjects sustained a stroke after the onset of migrainous visual symptoms: a subarachnoid hemorrhage 1 year later, an atherothrombotic brain stem infarct 3 years later, and a cardioembolic stroke 27 years later. In contrast, of 87 subjects with TIAs in the same cohort, 33% developed a stroke (P = 0.030), two thirds within 6 months of TIA onset.
CONCLUSIONS: Late-life-onset transient visual phenomena similar to the visual aura of migraine are not rare and often occur in the absence of headache. These symptoms appear not to be associated with an increased risk of stroke, and invasive diagnostic procedures or therapeutic measures are generally not indicated.

Entities:  

Mesh:

Year:  1998        PMID: 9707189     DOI: 10.1161/01.str.29.8.1539

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  13 in total

1.  Transient Ischemic Attack and Secondary Stroke.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

2.  Migraine with aura in patients over 50 years of age: the Marseille’s registry.

Authors:  Anne Donnet; Clément Daniel; Loïc Milandre; Julie Berbis; Pascal Auquier
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

Review 3.  Spreading Depression in Primary and Secondary Headache Disorders.

Authors:  Shih-Pin Chen; Cenk Ayata
Journal:  Curr Pain Headache Rep       Date:  2016-07

Review 4.  The risk of stroke in patients with migraine and implications for migraine management.

Authors:  Gretchen E Tietjen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Our evolving understanding of migraine with aura.

Authors:  Justin M DeLange; F Michael Cutrer
Journal:  Curr Pain Headache Rep       Date:  2014-10

Review 6.  Headache in the elderly: primary forms.

Authors:  Maria Clara Tonini; Gennaro Bussone
Journal:  Neurol Sci       Date:  2010-06       Impact factor: 3.307

Review 7.  Dissecting the association between migraine and stroke.

Authors:  Andrea M Harriott; Kevin M Barrett
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

Review 8.  Perceptive aspects of visual aura.

Authors:  Carlo Aleci; William Liboni
Journal:  Neurol Sci       Date:  2009-09-25       Impact factor: 3.307

9.  Diagnosis and misdiagnosis of cerebrovascular disease.

Authors:  Vasileios-Arsenios Lioutas; Shruti Sonni; Louis R Caplan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

Review 10.  Migraine in transient global amnesia: a meta-analysis of observational studies.

Authors:  Ioannis Liampas; Athanasios S Siouras; Vasileios Siokas; Zisis Tsouris; Dimitrios Rikos; Alexandros Brotis; Athina-Maria Aloizou; Metaxia Dastamani; Efthimios Dardiotis
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.